FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912759859> ?p ?o ?g. }

• W2912759859 endingPage "26" @default.
• W2912759859 startingPage "20" @default.
• W2912759859 abstract "Elayta (CT1812) is a novel allosteric antagonist of the sigma-2 receptor complex that prevents and displaces binding of Aβ oligomers to neurons. By stopping a key initiating event in Alzheimer's disease, this first-in-class drug candidate mitigates downstream synaptotoxicity and restores cognitive function in aged transgenic mouse models of Alzheimer's disease.A phase 1, two-part single and multiple ascending dose study was conducted in 7 and 4 cohorts of healthy human subjects, respectively. In part A, healthy, young subjects (<65 years old) received CT1812 doses ranging from 10 to 1120 mg (6:2 active to placebo [A:P] per cohort). In part B, subjects were administered 280, 560, and 840 mg once daily for 14 days (8:2 A:P per cohort). An elderly cohort, aged 65-75 years, was dosed at 560 mg once daily for 14 days (7:2 A:P). Serum concentrations of CT1812 in part B were measured on day 3 and 14 and cerebrospinal fluid concentrations on day 7 or 9. Cognitive testing was performed in the healthy elderly cohort at baseline and at day 14 of treatment.Treatment with CT1812 was well tolerated in all cohorts. Adverse events were mild to moderate in severity and included headache and GI tract symptoms. Plasma concentrations of drug were dose proportional across two orders of magnitude with minimal accumulation over 14 days. Cognitive scores in the healthy elderly cohort were similar before and after treatment.CT1812 was well tolerated with single dose administration up to 1120 mg and with multiple dose administration up to 840 mg and 560 mg in healthy young and healthy elderly subjects, respectively. CT1812 is currently being studied in early phase 2 trials in patients with Alzheimer's disease." @default.
• W2912759859 created "2019-02-21" @default.
• W2912759859 creator A5014646926 @default.
• W2912759859 creator A5036815556 @default.
• W2912759859 creator A5038848553 @default.
• W2912759859 creator A5040504105 @default.
• W2912759859 creator A5059020389 @default.
• W2912759859 creator A5059358741 @default.
• W2912759859 creator A5064805809 @default.
• W2912759859 creator A5081846952 @default.
• W2912759859 creator A5085923503 @default.
• W2912759859 creator A5091254879 @default.
• W2912759859 creator A5051491792 @default.
• W2912759859 creator A5055274812 @default.
• W2912759859 date "2018-12-18" @default.
• W2912759859 modified "2023-10-12" @default.
• W2912759859 title "A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease" @default.
• W2912759859 cites W1517529005 @default.
• W2912759859 cites W1985570437 @default.
• W2912759859 cites W2008752021 @default.
• W2912759859 cites W2015484447 @default.
• W2912759859 cites W2055775253 @default.
• W2912759859 cites W2063808031 @default.
• W2912759859 cites W2064145055 @default.
• W2912759859 cites W2079749054 @default.
• W2912759859 cites W2082248166 @default.
• W2912759859 cites W2107979600 @default.
• W2912759859 cites W2132365141 @default.
• W2912759859 cites W2329336071 @default.
• W2912759859 cites W2510806376 @default.
• W2912759859 cites W4211050998 @default.
• W2912759859 doi "https://doi.org/10.1016/j.trci.2018.11.001" @default.
• W2912759859 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6352291" @default.
• W2912759859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30723776" @default.
• W2912759859 hasPublicationYear "2018" @default.
• W2912759859 type Work @default.
• W2912759859 sameAs 2912759859 @default.
• W2912759859 citedByCount "62" @default.
• W2912759859 countsByYear W29127598592019 @default.
• W2912759859 countsByYear W29127598592020 @default.
• W2912759859 countsByYear W29127598592021 @default.
• W2912759859 countsByYear W29127598592022 @default.
• W2912759859 countsByYear W29127598592023 @default.
• W2912759859 crossrefType "journal-article" @default.
• W2912759859 hasAuthorship W2912759859A5014646926 @default.
• W2912759859 hasAuthorship W2912759859A5036815556 @default.
• W2912759859 hasAuthorship W2912759859A5038848553 @default.
• W2912759859 hasAuthorship W2912759859A5040504105 @default.
• W2912759859 hasAuthorship W2912759859A5051491792 @default.
• W2912759859 hasAuthorship W2912759859A5055274812 @default.
• W2912759859 hasAuthorship W2912759859A5059020389 @default.
• W2912759859 hasAuthorship W2912759859A5059358741 @default.
• W2912759859 hasAuthorship W2912759859A5064805809 @default.
• W2912759859 hasAuthorship W2912759859A5081846952 @default.
• W2912759859 hasAuthorship W2912759859A5085923503 @default.
• W2912759859 hasAuthorship W2912759859A5091254879 @default.
• W2912759859 hasBestOaLocation W29127598591 @default.
• W2912759859 hasConcept C126322002 @default.
• W2912759859 hasConcept C142724271 @default.
• W2912759859 hasConcept C170493617 @default.
• W2912759859 hasConcept C197934379 @default.
• W2912759859 hasConcept C204787440 @default.
• W2912759859 hasConcept C27081682 @default.
• W2912759859 hasConcept C2776885963 @default.
• W2912759859 hasConcept C2779134260 @default.
• W2912759859 hasConcept C71924100 @default.
• W2912759859 hasConcept C72563966 @default.
• W2912759859 hasConcept C98274493 @default.
• W2912759859 hasConceptScore W2912759859C126322002 @default.
• W2912759859 hasConceptScore W2912759859C142724271 @default.
• W2912759859 hasConceptScore W2912759859C170493617 @default.
• W2912759859 hasConceptScore W2912759859C197934379 @default.
• W2912759859 hasConceptScore W2912759859C204787440 @default.
• W2912759859 hasConceptScore W2912759859C27081682 @default.
• W2912759859 hasConceptScore W2912759859C2776885963 @default.
• W2912759859 hasConceptScore W2912759859C2779134260 @default.
• W2912759859 hasConceptScore W2912759859C71924100 @default.
• W2912759859 hasConceptScore W2912759859C72563966 @default.
• W2912759859 hasConceptScore W2912759859C98274493 @default.
• W2912759859 hasFunder F4320307132 @default.
• W2912759859 hasFunder F4320337337 @default.
• W2912759859 hasFunder F4320337359 @default.
• W2912759859 hasIssue "1" @default.
• W2912759859 hasLocation W29127598591 @default.
• W2912759859 hasLocation W29127598592 @default.
• W2912759859 hasLocation W29127598593 @default.
• W2912759859 hasLocation W29127598594 @default.
• W2912759859 hasOpenAccess W2912759859 @default.
• W2912759859 hasPrimaryLocation W29127598591 @default.
• W2912759859 hasRelatedWork W1977915442 @default.
• W2912759859 hasRelatedWork W2071535500 @default.
• W2912759859 hasRelatedWork W2085830368 @default.
• W2912759859 hasRelatedWork W2163740414 @default.
• W2912759859 hasRelatedWork W2374781999 @default.
• W2912759859 hasRelatedWork W2603773853 @default.
• W2912759859 hasRelatedWork W2952239533 @default.
• W2912759859 hasRelatedWork W2976934717 @default.
• W2912759859 hasRelatedWork W4233016836 @default.

• next